{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:00:06Z","timestamp":1793332806724,"version":"4.5.0"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,10,5]],"date-time":"2016-10-05T00:00:00Z","timestamp":1475625600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s00018-016-2393-9","type":"journal-article","created":{"date-parts":[[2016,10,5]],"date-time":"2016-10-05T05:40:40Z","timestamp":1475646040000},"page":"129-140","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":223,"title":["Cystic fibrosis: a clinical view"],"prefix":"10.1007","volume":"74","author":[{"given":"Carlo","family":"Castellani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baroukh M.","family":"Assael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,5]]},"reference":[{"key":"2393_CR1","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/archpedi.1938.01980140114013","volume":"56","author":"DH Andersen","year":"1938","unstructured":"Andersen DH (1938) Cystic fibrosis of the pancreas and its relation to celiac disease. Am J Dis Child 56:344\u2013399","journal-title":"Am J Dis Child"},{"key":"2393_CR2","unstructured":"http:\/\/www.cysticfibrosis.ca\/ . Accessed 1 Aug 2016"},{"key":"2393_CR3","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jcf.2013.12.002","volume":"13","author":"MN Hurley","year":"2014","unstructured":"Hurley MN, McKeever TM, Prayle AP, Fogarty AW, Smyth AR (2014) Rate of improvement of CF life expectancy exceeds that of general population\u2013observational death registration study. J Cyst Fibros 13:410\u2013415","journal-title":"J Cyst Fibros"},{"key":"2393_CR4","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1183\/09031936.00196314","volume":"46","author":"P-R Burgel","year":"2015","unstructured":"Burgel P-R, Bellis G, Olesen H, Viviani L, Zolin A, Blasi F, Elborn JS (2015) Future trends in cystic fibrosis demography in 34 European countries. Euro Respir J 46:133\u2013141","journal-title":"Euro Respir J"},{"key":"2393_CR5","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S2213-2600(13)70025-0","volume":"1","author":"BJ Plant","year":"2013","unstructured":"Plant BJ, Goss CH, Plant WD, Bell SC (2013) Management of comorbidities in older patients with cystic fibrosis. Lancet Respir Med 1:164\u2013174","journal-title":"Lancet Respir Med"},{"key":"2393_CR6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature04712","volume":"440","author":"DC Gadsby","year":"2006","unstructured":"Gadsby DC, Vergani P, Csan\u00e1dy L (2006) The ABC protein turned chloride channel whose failure causes cystic fibrosis. Nature 440:477\u2013483","journal-title":"Nature"},{"key":"2393_CR7","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/MCP.0b013e32834b14c9","volume":"17","author":"NW Keiser","year":"2011","unstructured":"Keiser NW, Engelhardt JF (2011) New animal models of cystic fibrosis: what are they teaching us? Curr Opin Pulm Med 17:478\u2013483","journal-title":"Curr Opin Pulm Med"},{"key":"2393_CR8","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jcf.2012.08.003","volume":"12","author":"D Ciro","year":"2013","unstructured":"Ciro D, Padoan R, Blau H, Marostica A, Fuoti M, Volpi S, Pilotta A, Meyerovitch J, Sher D, Assael BM (2013) Growth retardation and reduced growth hormone secretion in cystic fibrosis. Clinical observations from three CF centers. J Cyst Fibros 12:165\u2013169","journal-title":"J Cyst Fibros"},{"key":"2393_CR9","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1136\/jmg.2005.032839","volume":"43","author":"R Jin","year":"2006","unstructured":"Jin R, Hodges CA, Drumm ML, Palmert MR (2006) The cystic fibrosis transmembrane conductance regulator (CFTR) modulates the timing of puberty in mice. J Med Genet 43:e29","journal-title":"J Med Genet"},{"key":"2393_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/path.4753","author":"M Delion","year":"2016","unstructured":"Delion M, Braux J, Jourdain ML, Guillaume C, Bour C, Gangloff S, Le Pimpec-Barthes F, Sermet-Gaudelus I, Jacquot J, Velard F (2016) Over-expression of RANKL in osteoblasts: a possible mechanism of susceptibility to bone disease in cystic fibrosis. J Pathol. doi: 10.1002\/path.4753","journal-title":"J Pathol"},{"key":"2393_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0272-6386(03)00403-7","volume":"42","author":"EM Gibney","year":"2003","unstructured":"Gibney EM, Goldfarb DS (2003) The association of nephrolithiasis with cystic fibrosis. Am J Kidney Dis 42:1\u201311","journal-title":"Am J Kidney Dis"},{"key":"2393_CR12","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/jnci\/djs481","volume":"105","author":"P Maisonneuve","year":"2013","unstructured":"Maisonneuve P, Marshall BC, Knapp EA, Lowenfels AB (2013) Cancer risk in cystic Fibrosis: A 20-year nationwide study from the United States. J Natl Cancer Inst 105:122\u2013129","journal-title":"J Natl Cancer Inst"},{"key":"2393_CR13","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1097\/MCG.0000000000000034","volume":"48","author":"JL Billings","year":"2014","unstructured":"Billings JL, Dunitz JM, McAllister S, Herzog T, Bobr A, Khoruts A (2014) Early colon screening of adult patients with cystic fibrosis reveals high incidence of adenomatous colon polyps. J Clin Gastroenterol 48:e85\u2013e88","journal-title":"J Clin Gastroenterol"},{"key":"2393_CR14","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.mehy.2015.10.023","volume":"85","author":"A Azimi","year":"2015","unstructured":"Azimi A (2015) Cystic fibrosis could survive cholera, choleraics could survive cystic fibrosis, hypothesis that explores new horizon in treatmnet of cystic fibrosis. Med Hypoth 85:715\u2013717","journal-title":"Med Hypoth"},{"key":"2393_CR15","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1126\/science.2772657","volume":"245","author":"JM Rommens","year":"1989","unstructured":"Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, Dean M, Rozmahel R, Cole JL, Kennedy D, Hidaka N et al (1989) Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 245:1059\u20131065","journal-title":"Science"},{"key":"2393_CR16","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1126\/science.2570460","volume":"245","author":"B Kerem","year":"1989","unstructured":"Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, Buchwald M, Tsui LC (1989) Identification of the cystic fibrosis gene: genetic analysis. Science 245:1073\u20131080","journal-title":"Science"},{"key":"2393_CR17","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1126\/science.2475911","volume":"245","author":"JR Riordan","year":"1989","unstructured":"Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL et al (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245:1066\u20131073","journal-title":"Science"},{"key":"2393_CR18","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/ng.2745","volume":"45","author":"PR Sosnay","year":"2013","unstructured":"Sosnay PR, Siklosi KR, Van Goor F, Kaniecki K, Yu H, Sharma N, Ramalho AS, Amaral MD, Dorfman R, Zielenski J, Masica DL, Karchin R, Millen L, Thomas PJ, Patrinos GP, Corey M, Lewis MH, Rommens JM, Castellani C, Penland CM, Cutting GR (2013) Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet 45:1160\u20131167","journal-title":"Nat Genet"},{"key":"2393_CR19","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/0168-9525(92)90301-J","volume":"8","author":"LC Tsui","year":"1992","unstructured":"Tsui LC (1992) The spectrum of cystic fibrosis mutations. Trends Genet 8:392\u2013398","journal-title":"Trends Genet"},{"key":"2393_CR20","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/0092-8674(93)90353-R","volume":"73","author":"MJ Welsh","year":"1993","unstructured":"Welsh MJ, Smith AE (1993) Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 73:1251\u20131254","journal-title":"Cell"},{"key":"2393_CR21","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1146\/annurev.ge.29.120195.004021","volume":"29","author":"J Zielenski","year":"1995","unstructured":"Zielenski J, Tsui LC (1995) Cystic fibrosis: genotypic and phenotypic variations. Annu Rev Genet 29:777\u2013807","journal-title":"Annu Rev Genet"},{"key":"2393_CR22","first-page":"1","volume":"36","author":"C Bombieri","year":"2015","unstructured":"Bombieri C, Seia M, Castellani C (2015) Genotypes and Phenotypes in Cystic Fibrosis and Cystic Fibrosis Transmembrane Regulator-Related DisordersSemin Respir. Crit Care Med 36:1\u201314","journal-title":"Crit Care Med"},{"key":"2393_CR23","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/0021-9681(58)90185-1","volume":"7","author":"DH Andersen","year":"1958","unstructured":"Andersen DH (1958) Cystic fibrosis of the pancreas. J Chronic Dis 7:58\u201390","journal-title":"J Chronic Dis"},{"issue":"Suppl 2","key":"2393_CR24","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/S1569-1993(11)60014-3","volume":"10","author":"C Bombieri","year":"2011","unstructured":"Bombieri C, Claustres M, De Boeck K, Derichs N, Dodge J, Girodon E, Sermet I, Schwarz M, Tzetis M, Wilschanski M, Bareil C, Bilton D, Castellani C, Cuppens H, Cutting GR, Drev\u00ednek P, Farrell P, Elborn JS, Jarvi K, Kerem B, Kerem E, Knowles M, Macek M Jr, Munck A, Radojkovic D, Seia M, Sheppard DN, Southern KW, Stuhrmann M, Tullis E, Zielenski J, Pignatti PF, Ferec C (2011) Recommendations for the classification of diseases as CFTR-related disorders. J Cyst Fibros 10(Suppl 2):S86\u2013S102","journal-title":"J Cyst Fibros"},{"key":"2393_CR25","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJMoa051469","volume":"353","author":"ML Drumm","year":"2005","unstructured":"Drumm ML, Konstan MW, Schluchter MD, Handler A, Pace R, Zou F, Zariwala M, Fargo D, Xu A, Dunn JM, Darrah RJ, Dorfman R, Sandford AJ, Corey M, Zielenski J, Durie P, Goddard K, Yankaskas JR, Wright FA, Knowles MR, Gene Modifier Study Group (2005) Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med 353:1443\u20131453","journal-title":"N Engl J Med"},{"key":"2393_CR26","first-page":"409","volume":"125","author":"HB Hubert","year":"1982","unstructured":"Hubert HB, Fabsitz RR, Feinleib M, Gwinn C (1982) Genetic and environmental influences on pulmonary function in adult twins. Am Rev Respir Dis. 125:409\u2013415","journal-title":"Am Rev Respir Dis."},{"key":"2393_CR27","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1093\/geronj\/49.6.M264","volume":"49","author":"GE McClearn","year":"1994","unstructured":"McClearn GE, Svartengren M, Pedersen NL, Heller DA, Plomin R (1994) Genetic and environmental influences on pulmonary function in aging Swedish twins. J Gerontol. 49:264\u2013268","journal-title":"J Gerontol."},{"key":"2393_CR28","doi-asserted-by":"crossref","unstructured":"T\u00fcmmler B., Stanke F. (2014) Genetic and environmental modifiers of cystic fibrosis. In: Mall MA, Elborn JS (eds) Cystic fibrosis. ERS Monographs","DOI":"10.1183\/1025448x.10008813"},{"key":"2393_CR29","doi-asserted-by":"crossref","unstructured":"Knowles MR, Drumm M. (2012) The influence of genetics on cystic fibrosis phenotypes. Cold Spring Harb Perspect Med 2(12):a009548","DOI":"10.1101\/cshperspect.a009548"},{"key":"2393_CR30","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/jmg.2003.017947","volume":"41","author":"J Yarden","year":"2004","unstructured":"Yarden J, Radojkovic D, De Boeck K, Macek M Jr, Zemkova D, Vavrova V, Vlietinck R, Cassiman JJ, Cuppens H (2004) Polymorphisms in the mannose binding lectin gene affect the cystic fibrosis pulmonary phenotype. J Med Genet 41:629\u2013633","journal-title":"J Med Genet"},{"key":"2393_CR31","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/gene.2008.42","volume":"9","author":"AD Hillian","year":"2008","unstructured":"Hillian AD, Londono D, Dunn JM, Goddard KAB, Pace RG, Knowles MR, Drumm ML, CF Gene Modifier Study Group (2008) Modulation of cystic fibrosis lung disease by variants in interleukin-8. Genes Immun 9:501\u2013508","journal-title":"Genes Immun"},{"key":"2393_CR32","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/gene.2010.41","volume":"11","author":"M Chiarini","year":"2010","unstructured":"Chiarini M, Sabelli C, Melotti P, Garlanda C, Savoldi G, Mazza C, Padoan R, Plebani A, Mantovani A, Notarangelo LD, Assael BM, Badolato R (2010) PTX3 genetic variations affect the risk of Pseudomonas aeruginosa airway colonization in cystic fibrosis patients. Genes Immun 11:665\u2013670","journal-title":"Genes Immun"},{"key":"2393_CR33","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/ng.838","volume":"43","author":"FA Wright","year":"2011","unstructured":"Wright FA, Strug LJ, Doshi VK, Commander CW, Blackman SM, Sun L, Berthiaume Y, Cutler D, Cojocaru A, Collaco JM et al (2011) Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. Nat Genet 43:539\u2013546","journal-title":"Nat Genet"},{"key":"2393_CR34","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jpeds.2012.01.042","volume":"161","author":"DM Green","year":"2012","unstructured":"Green DM, Collaco JM, McDougal KE, Naughton KM, Blackman SM, Cutting GR (2012) Heritability of respiratory infection with Pseudomonas aeruginosa in cystic fibrosis. J Pediatr 161:290\u2013295","journal-title":"J Pediatr"},{"key":"2393_CR35","first-page":"1075","volume":"151","author":"TZ Khan","year":"1995","unstructured":"Khan TZ, Wagener JS, Bost T, Bost T, Martinez J, Accurso FJ, Riches DW (1995) Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 151:1075\u20131082","journal-title":"Am J Respir Crit Care Med"},{"key":"2393_CR36","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/resp.12521","volume":"20","author":"A Schultz","year":"2015","unstructured":"Schultz A, Stick S (2015) Early pulmonary inflammation and lung damage in children with cystic fibrosis. Respirology 20:569\u2013578","journal-title":"Respirology"},{"key":"2393_CR37","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nm.2715","volume":"18","author":"TS Cohen","year":"2012","unstructured":"Cohen TS, Prince A (2012) Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat Med 18:509\u2013519","journal-title":"Nat Med"},{"key":"2393_CR38","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1164\/rccm.201510-1922OC","volume":"193","author":"C Sorio","year":"2016","unstructured":"Sorio C, Montresor A, Bolomini-Vittori M, Caldrer S, Rossi B, Dusi S, Angiari S, Johansson JE, Vezzalini M, Leal T, Calcaterra E, Assael BM, Melotti P, Laudanna C (2016) Mutations of cystic fibrosis transmembrane conductance regulator gene cause a monocyte-selective adhesion deficiency. Am J Respir Crit Care Med 193:1123\u20131133","journal-title":"Am J Respir Crit Care Med"},{"key":"2393_CR39","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00281-016-0555-3","volume":"38","author":"AM Grabiec","year":"2016","unstructured":"Grabiec AM, Hussell T (2016) The role of airway macrophages in apoptotic cell clearance following acute and chronic lung inflammation. Semin Immunopathol. 38:409\u2013423","journal-title":"Semin Immunopathol."},{"key":"2393_CR40","first-page":"948367","volume":"2012","author":"JM Lee","year":"2012","unstructured":"Lee JM, Leach ST, Katz T, Day AS, Jaffe A, Ooi CY (2012) Update of faecal markers of inflammation in children with cystic fibrosis. Mediators Inflamm 2012:948367","journal-title":"Mediators Inflamm"},{"key":"2393_CR41","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jpeds.2008.05.005","volume":"153","author":"PM Farrell","year":"2008","unstructured":"Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, Durie PR, Legrys VA, Massie J, Parad RB, Rock MJ, Campbell PW 3rd (2008) Cystic Fibrosis Foundation. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 153:S4\u2013S14","journal-title":"J Pediatr"},{"key":"2393_CR42","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/thx.2005.043539","volume":"61","author":"K Boeck De","year":"2006","unstructured":"De Boeck K, Wilschanski M, Castellani C, Taylor C, Cuppens H, Dodge J, Sinaasappel M, on behalf of the Diagnostic Working Group (2006) Cystic fibrosis: terminology and diagnostic algorithms. Thorax 61:627\u2013635","journal-title":"Thorax"},{"key":"2393_CR43","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1089\/hum.1995.6.4-445","volume":"6","author":"MR Knowles","year":"1995","unstructured":"Knowles MR, Paradiso AM, Boucher RC (1995) In vivo nasal potential techniques and protocols for the assessment of the efficiency of gene transfer in cystic fibrosis. Hum Gene Ther 6:445\u2013455","journal-title":"Hum Gene Ther"},{"key":"2393_CR44","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jcf.2004.05.034","volume":"3","author":"HR Jonge De","year":"2004","unstructured":"De Jonge HR, Ballmann M, Veeze H, Bronsveld I, Stanke F, T\u00fcmmler B, Sinaasappel M (2004) Ex vivo CF diagnosis by intestinal current measurements (ICM) in small aperture, circulating Ussing chambers. J Cyst Fibros 3:159\u2013163","journal-title":"J Cyst Fibros"},{"key":"2393_CR45","first-page":"9","volume":"5","author":"MA Oronzo De","year":"2011","unstructured":"De Oronzo MA (2011) Hyperechogenic fetal bowel: an ultrasonographic marker for adverse fetal and neonatal outcome? J Prenatal Med 5:9\u201313","journal-title":"J Prenatal Med"},{"key":"2393_CR46","doi-asserted-by":"publisher","unstructured":"Castellani C, Massie J, Sontag M, Southern KW (2016) Newborn screening for cystic fibrosis. Lancet Respir Med. doi: 10.1016\/S2213-2600(16)00053-9","DOI":"10.1016\/S2213-2600(16)00053-9"},{"key":"2393_CR47","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1152\/physiol.00041.2006","volume":"22","author":"P Quinton","year":"2006","unstructured":"Quinton P (2006) Cystic fibrosis: lessons from the sweat gland. Physiology 22:212\u2013225","journal-title":"Physiology"},{"key":"2393_CR48","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1301725","volume":"368","author":"PD Sly","year":"2013","unstructured":"Sly PD, Gangell CL, Chen L, Ware RS, Ranganathan S, Mott LS, Murray CP, Stick SM, Investigators ARESTCF (2013) Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med 368:1963\u20131970","journal-title":"N Engl J Med"},{"key":"2393_CR49","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1136\/thx.2004.025924","volume":"59","author":"PD Sly","year":"2004","unstructured":"Sly PD, Brennan S (2004) Detecting early lung disease in cystic fibrosis: are current techniques sufficient? Thorax 59:1008\u20131010","journal-title":"Thorax"},{"key":"2393_CR50","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/ppul.10134","volume":"34","author":"HA Tiddens","year":"2002","unstructured":"Tiddens HA (2002) Detecting early structural lung damage in cystic fibrosis. Pediatr Pulmonol 34:228\u2013231","journal-title":"Pediatr Pulmonol"},{"key":"2393_CR51","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1378\/chest.12-2589","volume":"144","author":"LS Mott","year":"2013","unstructured":"Mott LS, Graniel KG, Park J, de Klerk NH, Sly PD, Murray CP, Tiddens HA, Stephen MS, Arest CF (2013) Assessment of early bronchiectasis in young children with cystic fibrosis is dependent on lung volume. Chest 144:1193\u20131198","journal-title":"Chest"},{"key":"2393_CR52","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1183\/13993003.00622-2015","volume":"46","author":"SJ Simpson","year":"2015","unstructured":"Simpson SJ, Ranganathan S, Park J, Turkovic L, Robins-Browne RM, Skoric B, Ramsey KA, Rosenow T, Banton GL, Berry L, Stick SM, Hall GL, Arest CF (2015) Progressive ventilation inhomogeneity in infants with cystic fibrosis after pulmonary infection. Eur Respir J 46:1680\u20131690","journal-title":"Eur Respir J"},{"key":"2393_CR53","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1183\/09059180.00006113","volume":"23","author":"AC Tang","year":"2014","unstructured":"Tang AC, Turvey SE, Alves MP, Regamey N, T\u00fcmmler B, Hartl D (2014) Current concepts: host-pathogen interactions in cystic fibrosis airways disease. Eur Respir Rev 23:320\u2013332","journal-title":"Eur Respir Rev"},{"key":"2393_CR54","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nature11130","volume":"487","author":"AA Pezzulo","year":"2012","unstructured":"Pezzulo AA, Tang XX, Hoegger MJ, Alaiwa MH, Ramachandran S, Moninger TO, Karp PH, Wohlford-Lenane CL, Haagsman HP, van Eijk M, B\u00e1nfi B, Horswill AR, Stoltz DA, McCray PB Jr, Welsh MJ, Zabner J (2012) Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature 487:109\u2013113","journal-title":"Nature"},{"key":"2393_CR55","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ccm.2015.10.003","volume":"37","author":"YJ Huang","year":"2016","unstructured":"Huang YJ, LiPuma JJ (2016) The Microbiome in Cystic Fibrosis. Clin Chest Med 37:59\u201367","journal-title":"Clin Chest Med"},{"key":"2393_CR56","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1586\/17476348.2015.1016504","volume":"9","author":"JL Justicia","year":"2015","unstructured":"Justicia JL, Sol\u00e9 A, Quintana-Gallego E, Gartner S, de Gracia J, Prados C, M\u00e1iz L (2015) Management of pulmonary exacerbations in cystic fibrosis: still an unmet medical need in clinical practice. Expert Rev Respir Med. 9:183\u2013194","journal-title":"Expert Rev Respir Med."},{"key":"2393_CR57","first-page":"461","volume":"1","author":"D\u00f6ring G, Flume P, Heijerman H, Elborn JS; Consensus Study Group","year":"2012","unstructured":"D\u00f6ring G, Flume P, Heijerman H, Elborn JS; Consensus Study Group (2012) Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros 1:461\u2013479","journal-title":"J Cyst Fibros"},{"key":"2393_CR58","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/MCP.0b013e32834b8c04","volume":"17","author":"AE Stenbit","year":"2011","unstructured":"Stenbit AE, Flume PA (2011) Pulmonary exacerbations in cystic fibrosis. Curr Opin Pulm Med. 17:442\u2013447","journal-title":"Curr Opin Pulm Med."},{"key":"2393_CR59","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/thx.52.4.318","volume":"52","author":"S Walter","year":"1997","unstructured":"Walter S, Gudowius P, Bosshammer J, R\u00f6mling U, Weissbrodt H, Sch\u00fcrmann W, von der Hardt H, T\u00fcmmler B (1997) Epidemiology of chronic Pseudomonas aeruginosa infections in the airways of lung transplant recipients with cystic fibrosis. Thorax 52:318\u2013321","journal-title":"Thorax"},{"key":"2393_CR60","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/ismej.2011.83","volume":"6","author":"SK Hansen","year":"2012","unstructured":"Hansen SK, Rau MH, Johansen HK, Ciofu O, Jelsbak L, Yang L, Folkesson A, Jarmer HO, Aan\u00e6s K, von Buchwald C, H\u00f8iby N, Molin S (2012) Evolution and diversification of Pseudomonas aeruginosa in the paranasal sinuses of cystic fibrosis children have implications for chronic lung infection. ISME J 6:31\u201345","journal-title":"ISME J"},{"key":"2393_CR61","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/MCP.0000000000000107","volume":"20","author":"EA Illing","year":"2014","unstructured":"Illing EA, Woodworth BA (2014) Management of the upper airway in cystic fibrosis. Curr Opin Pulm Med. 20:623\u2013631","journal-title":"Curr Opin Pulm Med."},{"key":"2393_CR62","doi-asserted-by":"crossref","first-page":"a009753","DOI":"10.1101\/cshperspect.a009753","volume":"3","author":"RC Lisle De","year":"2013","unstructured":"De Lisle RC, Borowitz D (2013) The Cystic Fibrosis Intestine. Cold Spring Harb Perspect Med 3:a009753","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2393_CR63","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1136\/adc.2006.107581","volume":"92","author":"M Cipolli","year":"2007","unstructured":"Cipolli M, Castellani C, Wilcken B, Massie J, McKay K, Gruca M, Tamanini A, Assael MB, Gaskin K (2007) Pancreatic phenotype in infants with cystic fibrosis identified by mutation screening. Arch Dis Child 92:842\u2013846","journal-title":"Arch Dis Child"},{"key":"2393_CR64","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jcf.2006.01.005","volume":"5","author":"A Daftary","year":"2006","unstructured":"Daftary A, Acton J, Heubi J, Amin R (2006) Fecal elastase-1: utility in pancreatic function in cystic fibrosis. J Cyst Fibros 5:71\u201376","journal-title":"J Cyst Fibros"},{"key":"2393_CR65","doi-asserted-by":"crossref","unstructured":"Dupuis A, Keenan K, Ooi CY, Dorfman R, Sontag MK, Naehrlich L, Castellani C, Strug LJ, Rommens JM, Gonska T (2016) Prevalence of meconium ileus marks the severity of mutations of the cystic fibrosistransmembrane conductance regulator (CFTR) gene. Genet Med 18:333\u2013340","DOI":"10.1038\/gim.2015.79"},{"key":"2393_CR66","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1203\/00006450-200003000-00010","volume":"47","author":"V Raia","year":"2000","unstructured":"Raia V, Maiuri L, de Ritis G, de Vizia B, Vacca L, Conte R, Auricchio S, Londei M (2000) Evidence of chronic inflammation in morphologically normal small intestine of cystic fibrosis patients. Pediatr Res 47:344\u2013350","journal-title":"Pediatr Res"},{"key":"2393_CR67","doi-asserted-by":"crossref","first-page":"22493","DOI":"10.1038\/srep22493","volume":"6","author":"O Manor","year":"2016","unstructured":"Manor O, Levy R, Pope CE, Hayden HS, Brittnacher MJ, Carr R, Radey MC, Hager KR, Heltshe SL, Ramsey BW, Miller SI, Hoffman LR, Borenstein E (2016) Metagenomic evidence for taxonomic dysbiosis and functional imbalance in the gastrointestinal tracts of children with cystic fibrosis. Sci Rep. 6:22493","journal-title":"Sci Rep."},{"key":"2393_CR68","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.biocel.2014.02.005","volume":"52","author":"A Munck","year":"2014","unstructured":"Munck A (2014) Cystic fibrosis: evidence for gut inflammation. Int J Biochem Cell Biol 52:180\u2013183","journal-title":"Int J Biochem Cell Biol"},{"key":"2393_CR69","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jcf.2012.11.010","volume":"12","author":"T Flass","year":"2013","unstructured":"Flass T, Narkewicz MR (2013) Cirrhosis and other liver disease in cystic fibrosis. J Cyst Fibros 12:116\u2013124","journal-title":"J Cyst Fibros"},{"key":"2393_CR70","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/1096-8628(20010201)98:4<294::AID-AJMG1097>3.0.CO;2-K","volume":"98","author":"G Castaldo","year":"2001","unstructured":"Castaldo G, Fuccio A, Salvatore D, Raia V, Santostasi T, Leonardi S, Lizzi N, La Rosa M, Rigillo N, Salvatore F (2001) Liver expression in cystic fibrosis could be modulated by genetic factors different from the cystic fibrosis transmembrane regulator genotype. Am J Med Genet 98:294\u2013297","journal-title":"Am J Med Genet"},{"key":"2393_CR71","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/MPG.0b013e3182432034","volume":"54","author":"TN Pereira","year":"2012","unstructured":"Pereira TN, Lewindon PJ, Greer RM, Hoskins AC, Williamson RM, Shepherd RW, Ramm GA (2012) Transcriptional basis for hepatic fibrosis in cystic fibrosis-associated liver disease. J Pediatr Gastroenterol Nutr 54:328\u2013335","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2393_CR72","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1001\/jama.2009.1295","volume":"302","author":"JR Bartlett","year":"2009","unstructured":"Bartlett JR, Friedman KJ, Ling SC, Pace RG, Bell SC, Bourke B, Castaldo G, Castellani C, Cipolli M, Colombo C, Colombo JL, Debray D, Fernandez A, Lacaille F, Macek M Jr, Rowland M, Salvatore F, Taylor CJ, Wainwright C, Wilschanski M, Zemkov\u00e1 D, Hannah WB, Phillips MJ, Corey M, Zielenski J, Dorfman R, Wang Y, Zou F, Silverman LM, Drumm ML, Wright FA, Lange EM, Durie PR, Knowles MR, Gene Modifier Study Group (2009) Genetic modifiers of liver disease in cystic fibrosis. JAMA 302:1076\u20131083","journal-title":"JAMA"},{"key":"2393_CR73","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jcf.2013.02.008","volume":"12","author":"A Kelly","year":"2013","unstructured":"Kelly A, Moran A (2013) Update on cystic fibrosis-related diabetes. J Cyst Fibros 12:318\u2013331. doi: 10.1016\/j.jcf.2013.02.008 (Erratum. In: J Cyst Fibros. 2014;13:119)","journal-title":"J Cyst Fibros"},{"issue":"Suppl 2","key":"2393_CR74","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S1569-1993(11)60004-0","volume":"10","author":"I Sermet-Gaudelus","year":"2011","unstructured":"Sermet-Gaudelus I, Bianchi ML, Garab\u00e9dian M, Aris RM, Morton A, Hardin DS, Elkin SL, Compston JE, Conway SP, Castanet M, Wolfe S, Haworth CS (2011) European cystic fibrosis bone mineralisation guidelines. J Cyst Fibros 10(Suppl 2):S16\u2013S23","journal-title":"J Cyst Fibros"},{"issue":"2","key":"2393_CR75","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s001980200007","volume":"13","author":"RM Aris","year":"2002","unstructured":"Aris RM, Ontjes DA, Buell HE, Blackwood AD, Lark RK, Caminiti M, Brown SA, Renner JB, Chalermskulrat W, Lester GE (2002) Osteoporos Int 13(2):151\u2013157","journal-title":"Osteoporos Int"},{"key":"2393_CR76","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1136\/thx.2006.075887","volume":"62","author":"EF Shead","year":"2007","unstructured":"Shead EF, Haworth CS, Condliffe AM, McKeon DJ, Scott MA, Compston JE (2007) Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in human bone. Thorax 62:650\u2013651","journal-title":"Thorax"},{"key":"2393_CR77","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/humrep\/der377","volume":"27","author":"J Yu","year":"2012","unstructured":"Yu J, Chen Z, Ni Y, Li Z (2012) CFTR mutations in men with congenital bilateral absence of the vas deferens (CBAVD): a systemic review and meta-analysis. Hum Reprod 27:25\u201335","journal-title":"Hum Reprod"},{"key":"2393_CR78","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1007\/BF03343794","volume":"23","author":"C Quinzii","year":"2000","unstructured":"Quinzii C, Castellani C (2000) The cystic fibrosis transmembrane regulator gene and male infertility. J Endocrinol Invest 23:684\u2013689","journal-title":"J Endocrinol Invest"},{"key":"2393_CR79","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/ppul.21001","volume":"44","author":"BM Assael","year":"2009","unstructured":"Assael BM, Casazza G, Iansa P, Volpi S, Milani S (2009) Growth and long-term lung function in cystic fibrosis: a longitudinal study of patients diagnosed by neonatal screening. Pediatr Pulmonol 44:209\u2013215","journal-title":"Pediatr Pulmonol"},{"key":"2393_CR80","doi-asserted-by":"crossref","first-page":"20571","DOI":"10.1073\/pnas.1015281107","volume":"107","author":"MP Rogan","year":"2010","unstructured":"Rogan MP, Reznikov LR, Pezzulo AA, Gansemer ND, Samuel M, Prather RS, Zabner J, Fredericks DC, McCray PB Jr, Welsh MJ, Stoltz DA (2010) Pigs and humans with cystic fibrosis have reduced insulin-like growth factor 1 (IGF1) levels at birth. Proc Natl Acad Sci U S A. 107:20571\u201320575","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"Suppl 1","key":"2393_CR81","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jcf.2014.03.009","volume":"13","author":"S Conway","year":"2014","unstructured":"Conway S, Balfour-Lynn IM, De Rijcke K, Drevinek P, Foweraker J, Havermans T, Heijerman H, Lannefors L, Lindblad A, Macek M, Madge S, Moran M, Morrison L, Morton A, Noordhoek J, Sands D, Vertommen A, Peckham D (2014) European Cystic Fibrosis Society Standards of Care: framework for the Cystic Fibrosis Centre. J Cyst Fibros 13(Suppl 1):S3\u2013S22","journal-title":"J Cyst Fibros"},{"key":"2393_CR82","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/0895-4356(88)90063-7","volume":"41","author":"M Corey","year":"1988","unstructured":"Corey M, McLaughlin FJ, Williams M, Levison H (1988) A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. J Clin Epidemiol 41:583\u2013591","journal-title":"J Clin Epidemiol"},{"key":"2393_CR83","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.clnu.2016.03.004","volume":"35","author":"D Turck","year":"2016","unstructured":"Turck D, Braegger CP, Colombo C, Declercq D, Morton A, Pancheva R, Robberecht E, Stern M, Strandvik B, Wolfe S, Schneider SM, Wilschanski M (2016) ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis. Clin Nutr. 35:557\u2013577","journal-title":"Clin Nutr."},{"key":"2393_CR84","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/MPG.0b013e3182618f33","volume":"55","author":"A Maqbool","year":"2012","unstructured":"Maqbool A, Schall JI, Gallagher PR, Zemel BS, Strandvik B, Stallings VA (2012) Relation between dietary fat intake type and serum fatty acid status in children with cystic fibrosis. J Pediatr Gastroenterol Nutr 55:605\u2013611","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2393_CR85","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.plefa.2010.07.002","volume":"83","author":"B Strandvik","year":"2010","unstructured":"Strandvik B (2010) Fatty acid metabolism in cystic fibrosis. Prostaglandins Leukot Essent Fatty Acids 83:121\u2013129","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"2393_CR86","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/MPG.0b013e31817fb76b","volume":"4","author":"A Maqbool","year":"2008","unstructured":"Maqbool A, Schall JI, Garcia-Espana JF, Zemel BS, Strandvik B, Stallings VA (2008) Serum linoleic acid status as a clinical indicator of essential fatty acid status in children with cystic fibrosis. J Pediatr Gastroenterol Nutr 4:635\u2013644","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2393_CR87","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1093\/ajcn\/63.5.746","volume":"63","author":"AW Egmond van","year":"1996","unstructured":"van Egmond AW, Kosorok MR, Koscik R, Laxova A, Farrell PM (1996) Effect of linoleic acid intake on growth of infants with cystic fibrosis. Am J Clin Nutr 63:746\u2013752","journal-title":"Am J Clin Nutr"},{"key":"2393_CR88","doi-asserted-by":"crossref","unstructured":"Morrell MR, Pilewski JM (2016) Lung transplantation for cystic fibrosis. Clin Chest Med 37:127\u2013138","DOI":"10.1016\/j.ccm.2015.11.008"},{"key":"2393_CR89","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1055\/s-0035-1547347","volume":"36","author":"JP Lynch 3rd","year":"2015","unstructured":"Lynch JP 3rd, Sayah DM, Belperio JA, Weigt SS (2015) Lung transplantation for cystic fibrosis: results, indications, complications, and controversies. Semin Respir Crit Care Med. 36:299\u2013320","journal-title":"Semin Respir Crit Care Med."},{"key":"2393_CR90","first-page":"69","volume":"15","author":"L Leeuwen","year":"2014","unstructured":"Leeuwen L, Fitzgerald DA, Gaskin KJ (2014) Liver disease in cystic fibrosis. Paediatr Respir Rev 15:69\u201374","journal-title":"Paediatr Respir Rev"},{"key":"2393_CR91","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1002\/lary.25210","volume":"125","author":"A Hughes","year":"2015","unstructured":"Hughes A, Adil EA (2015) What is the role of endoscopic sinus surgery in adult patients with cystic fibrosis? Laryngoscope 125:2018\u20132020","journal-title":"Laryngoscope"},{"key":"2393_CR92","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jpeds.2007.04.009","volume":"151","author":"LC Lands","year":"2007","unstructured":"Lands LC, Milner R, Cantin AM, Manson D, Corey M (2007) High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J Pediatr 151:249\u2013254","journal-title":"J Pediatr"},{"key":"2393_CR93","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1183\/09031936.00136712","volume":"42","author":"P Spagnolo","year":"2013","unstructured":"Spagnolo P, Fabbri LM, Bush A (2013) Long-term macrolide treatment for chronic respiratory disease. Eur Respir J 42:239\u2013251","journal-title":"Eur Respir J"},{"key":"2393_CR94","doi-asserted-by":"crossref","unstructured":"Southern KW, Barker PM, Solis-Moya A, Patel L (2012) Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 11:CD002203","DOI":"10.1002\/14651858.CD002203.pub4"},{"key":"2393_CR95","doi-asserted-by":"publisher","unstructured":"Lee TW, Southern KW, Perry LA, Penny-Dimri JC, Aslam AA (2016) Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease. Cochrane Database Syst Rev 17:CD005599. doi: 10.1002\/14651858.CD005599.pub5","DOI":"10.1002\/14651858.CD005599.pub5"},{"key":"2393_CR96","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/mt.2012.32","volume":"20","author":"M Oakland","year":"2012","unstructured":"Oakland M, Sinn PL, McCray PB Jr (2012) Advances in cell and gene-based therapies for cystic fi brosis lung disease. Mol Ther 20:1108\u20131115","journal-title":"Mol Ther"},{"key":"2393_CR97","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S2213-2600(15)00245-3","volume":"3","author":"EW Alton","year":"2015","unstructured":"Alton EW, Armstrong DK, Ashby D, Bayfield KJ, Bilton D, Bloomfield EV, Boyd AC, Brand J, Buchan R, Calcedo R, Carvelli P, Chan M, Cheng SH, Collie DD, Cunningham S, Davidson HE, Davies G, Davies JC, Davies LA, Dewar MH, Doherty A, Donovan J, Dwyer NS, Elgmati HI, Featherstone RF, Gavino J, Gea-Sorli S, Geddes DM, Gibson JS, Gill DR, Greening AP, Griesenbach U, Hansell DM, Harman K, Higgins TE, Hodges SL, Hyde SC, Hyndman L, Innes JA, Jacob J, Jones N, Keogh BF, Limberis MP, Lloyd-Evans P, Maclean AW, Manvell MC, McCormick D, McGovern M, McLachlan G, Meng C, Montero MA, Milligan H, Moyce LJ, Murray GD, Nicholson AG, Osadolor T, Parra-Leiton J, Porteous DJ, Pringle IA, Punch EK, Pytel KM, Quittner AL, Rivellini G, Saunders CJ, Scheule RK, Sheard S, Simmonds NJ, Smith K, Smith SN, Soussi N, Soussi S, Spearing EJ, Stevenson BJ, Sumner-Jones SG, Turkkila M, Ureta RP, Waller MD, Wasowicz MY, Wilson JM, Wolstenholme-Hogg P, UK Cystic Fibrosis Gene Therapy Consortium (2015) Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med. 3:684\u2013691","journal-title":"Lancet Respir Med."},{"key":"2393_CR98","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1006\/mthe.2002.0639","volume":"6","author":"PL Zeitlin","year":"2002","unstructured":"Zeitlin PL, Diener-West M, Rubenstein RC, Boyle MP, Lee CK, Brass-Ernst L (2002) Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. Mol Ther 6:119\u2013126","journal-title":"Mol Ther"},{"key":"2393_CR99","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1164\/rccm.201303-0427OC","volume":"188","author":"M Griese","year":"2013","unstructured":"Griese M, Kappler M, Eismann C, Ballmann M, Junge S, Rietschel E, van Koningsbruggen-Rietschel S, Staab D, Rolinck-Werninghaus C, Mellies U, K\u00f6hnlein T, Wagner T, K\u00f6nig S, Teschler H, Heuer HE, Kopp M, Heyder S, Hammermann J, K\u00fcster P, Honer M, Mansmann U, Beck-Speier I, Hartl D, Fuchs C, Glutathione Study Group, Hector A (2013) Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized clinical trial. Am J Respir Crit Care Med. 188:83\u201389","journal-title":"Am J Respir Crit Care Med."},{"key":"2393_CR100","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1159\/000445648","volume":"39","author":"C Adams","year":"2016","unstructured":"Adams C, Icheva V, Deppisch C, Lauer J, Herrmann G, Graepler-Mainka U, Heyder S, Gulbins E, Riethmueller J (2016) Long-Term Pulmonal Therapy of Cystic Fibrosis-Patients with Amitriptyline. Cell Physiol Biochem 39:565\u2013572","journal-title":"Cell Physiol Biochem"},{"key":"2393_CR101","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1159\/000350071","volume":"31","author":"L N\u00e4hrlich","year":"2013","unstructured":"N\u00e4hrlich L, Mainz JG, Adams C, Engel C, Herrmann G, Icheva V, Lauer J, Deppisch C, Wirth A, Unger K, Graepler-Mainka U, Hector A, Heyder S, Stern M, D\u00f6ring G, Gulbins E, Riethm\u00fcller J (2013) Therapy of CF-patients with amitriptyline and placebo\u2013a randomised, double-blind, placebo-controlled phase IIb multicenter, cohort-study. Cell Physiol Biochem 31:505\u2013512","journal-title":"Cell Physiol Biochem"},{"key":"2393_CR102","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1165\/rcmb.2009-0174OC","volume":"42","author":"KA Becker","year":"2010","unstructured":"Becker KA, Riethm\u00fcller J, L\u00fcth A, D\u00f6ring G, Kleuser B, Gulbins E (2010) Acid sphingomyelinase inhibitors normalize pulmonary ceramide and inflammation in cystic fibrosis. Am J Respir Cell Mol Biol 42:716\u2013724","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2393_CR103","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000227814","volume":"24","author":"J Riethm\u00fcller","year":"2009","unstructured":"Riethm\u00fcller J, Anthonysamy J, Serra E, Schwab M, D\u00f6ring G, Gulbins E (2009) Therapeutic efficacy and safety of amitriptyline in patients with cystic fibrosis. Cell Physiol Biochem 24:65\u201372","journal-title":"Cell Physiol Biochem"},{"key":"2393_CR104","doi-asserted-by":"crossref","unstructured":"Dey I, Shah K, Bradbury NA (2016) Natural Compounds as Therapeutic Agents in the Treatment Cystic Fibrosis. J Genet Syndr Gene Ther 7pii: 284","DOI":"10.4172\/2157-7412.1000284"},{"key":"2393_CR105","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jpeds.2012.11.034","volume":"162","author":"RB Moss","year":"2013","unstructured":"Moss RB (2013) Pitfalls of drug development: lessons learned from trials of denufosol in cystic fibrosis. J Pediatr 162:676\u2013680","journal-title":"J Pediatr"},{"key":"2393_CR106","unstructured":"ClinicalTrials.gov Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (ROSCO-CF) Last verified July 2016"},{"key":"2393_CR107","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1183\/09031936.00017713","volume":"43","author":"M Fayon","year":"2014","unstructured":"Fayon M, Kent L, Bui S, Dupont L, Sermet I (2014) European Cystic Fibrosis Society Clinical Trial Network Standardisation Committee. Clinimetric properties of bronchoalveolar lavage inflammatory markers in cystic fibrosis. Eur Respir J 43:610\u2013626","journal-title":"Eur Respir J"},{"key":"2393_CR108","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1164\/ajrccm.161.3.9904116","volume":"161","author":"M Wilschanski","year":"2000","unstructured":"Wilschanski M, Famini C, Blau H, Rivlin J, Augarten A, Avital A, Kerem B, Kerem E (2000) A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. Am J Respir Crit Care Med 161:860\u2013865","journal-title":"Am J Respir Crit Care Med"},{"key":"2393_CR109","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1056\/NEJMoa022170","volume":"349","author":"M Wilschanski","year":"2003","unstructured":"Wilschanski M, Yahav Y, Yaacov Y, Blau H, Bentur L, Rivlin J, Aviram M, Bdolah-Abram T, Bebok Z, Shushi L, Kerem B, Kerem E (2003) Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 349:1433\u20131441","journal-title":"N Engl J Med"},{"key":"2393_CR110","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1164\/rccm.201001-0137OC","volume":"182","author":"I Sermet-Gaudelus","year":"2010","unstructured":"Sermet-Gaudelus I, Boeck KD, Casimir GJ, Vermeulen F, Leal T, Mogenet A, Roussel D, Fritsch J, Hanssens L, Hirawat S, Miller NL, Constantine S, Reha A, Ajayi T, Elfring GL, Miller LL (2010) Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med 182:1262\u20131272","journal-title":"Am J Respir Crit Care Med"},{"key":"2393_CR111","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1183\/09031936.00057512","volume":"4","author":"K Boeck De","year":"2013","unstructured":"De Boeck K, Kent L, Davies J, Derichs N, Amaral M, Rowe SM, Middleton P, de Jonge H, Bronsveld I, Wilschanski M, Melotti P, Danner-Boucher I, Boerner S, Fajac I, Southern K, de Nooijer RA, Bot A, de Rijke Y, de Wachter E, Leal T, Vermeulen F, Hug MJ, Rault G, Nguyen-Khoa T, Barreto C, Proesmans M, Sermet-Gaudelus I, European Cystic Fibrosis Society Clinical Trial Network Standardisation Committee (2013) CFTR biomarkers: time for promotion to surrogate end-point. Eur Respir J 4:203\u2013216","journal-title":"Eur Respir J"},{"key":"2393_CR112","doi-asserted-by":"crossref","unstructured":"Dekkers JF, Berkers G, Kruisselbrink E, Vonk A, de Jonge HR, Janssens HM, Bronsveld I, van de Graaf EA, Nieuwenhuis EE, Houwen RH, Vleggaar FP, Escher JC, de Rijke YB, Majoor CJ, Heijerman HG, de Winter-de Groot KM, Clevers H, van der Ent CK, Beekman JM (2016) Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis. Sci Transl Med 8:344ra84","DOI":"10.1126\/scitranslmed.aad8278"},{"key":"2393_CR113","doi-asserted-by":"publisher","unstructured":"Dekkers JF, Van Mourik P, Vonk AM, Kruisselbrink E, Berkers G, de Winter-de Groot KM, Janssens HM, Bronsveld I, van der Ent CK, de Beekman JM (2016) Potentiator synergy in rectal organoids carrying S1251N, G551D, or F508del CFTR mutations. J Cyst Fibros. doi: 10.1016\/j.jcf.2016.04.007","DOI":"10.1016\/j.jcf.2016.04.007"},{"key":"2393_CR114","doi-asserted-by":"publisher","unstructured":"Dekkers JF, Gogorza Gondra RA, Kruisselbrink E, Vonk AM, Janssens HM, de Winter-de Groot KM, van der Ent CK, Beekman JM (2016) Optimal correction of distinct CFTR folding mutants in rectal cystic fibrosis organoids. Eur Respir J. doi: 10.1183\/13993003.01192-2015","DOI":"10.1183\/13993003.01192-2015"},{"key":"2393_CR115","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1164\/rccm.201505-0914OC","volume":"193","author":"D Vidovi\u0107","year":"2016","unstructured":"Vidovi\u0107 D, Carlon MS, da Cunha MF, Dekkers JF, Hollenhorst MI, Bijvelds MJ, Ramalho AS, Van den Haute C, Ferrante M, Baekelandt V, Janssens HM, De Boeck K, Sermet-Gaudelus I, de Jonge HR, Gijsbers R, Beekman JM, Edelman A, Debyser Z (2016) rAAV-CFTR\u0394R Rescues the cystic fibrosis phenotype in human intestinal organoids and cystic fibrosis mice. Am J Respir Crit Care Med 193:288\u2013298","journal-title":"Am J Respir Crit Care Med"},{"key":"2393_CR116","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S2213-2600(14)70100-6","volume":"2","author":"Kerem E, Konstan MW, De Boeck K, Accurso FJ, Sermet-Gaudelus I, Wilschanski M, Elborn JS, Melotti P, Bronsveld I, Fajac I, Malfroot A, Rosenbluth DB, Walker PA, McColley SA, Knoop C, Quattrucci S, Rietschel E, Zeitlin PL, Barth J, Elfring GL, Welch EM, Branstrom A, Spiegel RJ, Peltz SW, Ajayi T, Rowe SM; Cystic Fibrosis Ataluren Study Group","year":"2014","unstructured":"Kerem E, Konstan MW, De Boeck K, Accurso FJ, Sermet-Gaudelus I, Wilschanski M, Elborn JS, Melotti P, Bronsveld I, Fajac I, Malfroot A, Rosenbluth DB, Walker PA, McColley SA, Knoop C, Quattrucci S, Rietschel E, Zeitlin PL, Barth J, Elfring GL, Welch EM, Branstrom A, Spiegel RJ, Peltz SW, Ajayi T, Rowe SM; Cystic Fibrosis Ataluren Study Group (2014) Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med. 2:539\u2013547","journal-title":"Lancet Respir Med."},{"key":"2393_CR117","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","volume":"365","author":"Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, D\u0159ev\u00ednek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordo\u00f1ez C, Elborn JS; VX08-770-102 Study Group","year":"2011","unstructured":"Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, D\u0159ev\u00ednek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordo\u00f1ez C, Elborn JS; VX08-770-102 Study Group (2011) A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 365:1663\u20131672","journal-title":"N Engl J Med"},{"key":"2393_CR118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta18180","volume":"18","author":"P Whiting","year":"2014","unstructured":"Whiting P, Al M, Burgers L, Westwood M, Ryder S, Hoogendoorn M, Armstrong N, Allen A, Severens H, Kleijnen J (2014) Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis. Health Technol Assess 18:1\u2013106","journal-title":"Health Technol Assess"},{"key":"2393_CR119","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S2213-2600(15)00201-5","volume":"3","author":"Moss RB, Flume PA, Elborn JS, Cooke J, Rowe SM, McColley SA, Rubenstein RC, Higgins M; VX11-770-110 (KONDUCT) Study Group","year":"2015","unstructured":"Moss RB, Flume PA, Elborn JS, Cooke J, Rowe SM, McColley SA, Rubenstein RC, Higgins M; VX11-770-110 (KONDUCT) Study Group (2015) Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Lancet Respir Med. 3:524\u2013533","journal-title":"Lancet Respir Med."},{"key":"2393_CR120","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jcf.2014.09.005","volume":"13","author":"K Boeck De","year":"2014","unstructured":"De Boeck K, Munck A, Walker S, Faro A, Hiatt P, Gilmartin G, Higgins M (2014) Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. J Cyst Fibros 13:674\u2013680","journal-title":"J Cyst Fibros"},{"key":"2393_CR121","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","volume":"373","author":"Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF, Munck A, Ratjen F, Rowe SM, Waltz D, Boyle MP; TRAFFIC Study Group; TRANSPORT Study Group","year":"2015","unstructured":"Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF, Munck A, Ratjen F, Rowe SM, Waltz D, Boyle MP; TRAFFIC Study Group; TRANSPORT Study Group (2015) Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med 373:220\u2013231","journal-title":"N Engl J Med"},{"key":"2393_CR122","unstructured":"https:\/\/www.cff.org\/Trials\/pipeline . Accessed 1 Aug 2016"},{"key":"2393_CR123","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.4161\/15548627.2014.973737","volume":"10","author":"D Stefano De","year":"2014","unstructured":"De Stefano D, Villella VR, Esposito S, Tosco A, Sepe A, De Gregorio F, Salvadori L, Grassia R, Leone CA, De Rosa G, Maiuri MC, Pettoello-Mantovani M, Guido S, Bossi A, Zolin A, Venerando A, Pinna LA, Mehta A, Bona G, Kroemer G, Maiuri L, Raia V (2014) Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation. Autophagy. 10:2053\u20132074","journal-title":"Autophagy."},{"key":"2393_CR124","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/cdd.2016.22","volume":"23","author":"A Tosco","year":"2016","unstructured":"Tosco A, De Gregorio F, Esposito S, De Stefano D, Sana I, Ferrari E, Sepe A, Salvadori L, Buonpensiero P, Di Pasqua A, Grassia R, Leone CA, Guido S, De Rosa G, Lusa S, Bona G, Stoll G, Maiuri MC, Mehta A, Kroemer G, Maiuri L, Raia V (2016) A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR. Cell Death Differ 23:1380\u20131393","journal-title":"Cell Death Differ"},{"key":"2393_CR125","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1378\/chest.12-1639","volume":"143","author":"LR Hoffman","year":"2013","unstructured":"Hoffman LR, Ramsey BW (2013) Cystic fibrosis therapeutics: the road ahead. Chest 143:207\u2013213","journal-title":"Chest"},{"key":"2393_CR126","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMe1110323","volume":"365","author":"PB Davis","year":"2011","unstructured":"Davis PB (2011) Therapy for cystic fibrosis\u2014the end of the beginning? N Engl J Med 365:1734\u20131735","journal-title":"N Engl J Med"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-016-2393-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00018-016-2393-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-016-2393-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T15:47:51Z","timestamp":1657381671000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00018-016-2393-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,5]]},"references-count":126,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["2393"],"URL":"https:\/\/doi.org\/10.1007\/s00018-016-2393-9","relation":{},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,5]]}}}